Log in

NASDAQ:APTXAptinyx Stock Price, Forecast & News

-0.03 (-0.75 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $3.95
50-Day Range
MA: $4.29
52-Week Range
Now: $3.95
Volume172,112 shs
Average Volume256,704 shs
Market Capitalization$180.36 million
P/E RatioN/A
Dividend YieldN/A
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Read More
Aptinyx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APTX



Sales & Book Value

Annual Sales$3.67 million
Book Value$2.31 per share


Net Income$-57,410,000.00
Net Margins-1,540.42%


Market Cap$180.36 million
Next Earnings Date8/13/2020 (Confirmed)
OptionableNot Optionable
-0.03 (-0.75 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aptinyx (NASDAQ:APTX) Frequently Asked Questions

How has Aptinyx's stock been impacted by COVID-19 (Coronavirus)?

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APTX shares have increased by 62.6% and is now trading at $3.95.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Aptinyx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptinyx

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Aptinyx

How can I listen to Aptinyx's earnings call?

Aptinyx will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Aptinyx's earnings last quarter?

Aptinyx Inc (NASDAQ:APTX) announced its earnings results on Thursday, May, 14th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The business had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative net margin of 1,540.42% and a negative return on equity of 47.99%.
View Aptinyx's earnings history

What price target have analysts set for APTX?

6 brokerages have issued 1 year price objectives for Aptinyx's shares. Their forecasts range from $7.00 to $15.00. On average, they anticipate Aptinyx's share price to reach $9.67 in the next twelve months. This suggests a possible upside of 144.7% from the stock's current price.
View analysts' price targets for Aptinyx

Has Aptinyx been receiving favorable news coverage?

Media coverage about APTX stock has trended very positive on Saturday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Aptinyx

Are investors shorting Aptinyx?

Aptinyx saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 912,900 shares, a drop of 10.5% from the July 15th total of 1,020,000 shares. Based on an average daily trading volume, of 421,500 shares, the days-to-cover ratio is presently 2.2 days. Approximately 4.1% of the shares of the stock are short sold.
View Aptinyx's Current Options Chain

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:
  • Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
  • Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
  • Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
  • Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)

When did Aptinyx IPO?

(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.45%), Meridian Wealth Management LLC (0.07%), New York State Common Retirement Fund (0.05%), Leap Investments LP (0.03%) and UBS Group AG (0.02%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen.
View institutional ownership trends for Aptinyx

Which major investors are buying Aptinyx stock?

APTX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meridian Wealth Management LLC, New York State Common Retirement Fund, Leap Investments LP, and UBS Group AG. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen.
View insider buying and selling activity for Aptinyx

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $3.95.

How big of a company is Aptinyx?

Aptinyx has a market capitalization of $180.36 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

What is Aptinyx's official website?

The official website for Aptinyx is www.aptinyx.com.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.